Pirfenidone

Nature Reviews Drug Discovery

Volumn 10, Issue 7, 2011, Pages 489-490

  Richeldi, Luca ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CC 930; FG 3019; INTEDANIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GS 6624; PIRFENIDONE; PLACEBO; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LUNG FIBROSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES;

EID: 79960053071     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3495     Document Type: Note

References (9)

1. Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788-824 (2011).
2. du Bois, R. M. Strategies for treating idiopathic pulmonary fibrosis. Nature Rev. Drug Discov. 9, 129-140 (2010).
3. Iyer, S. N. et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125, 779-785 (1995).
4. Iyer, S. N. et al. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 29, 367-373 (1999). (Pubitemid 29451612)
5. European Medicines Agency (EMA). European Public Assessment Report-Esbriet. EMA website [online], http://www.ema.europa.eu/docs/en-GB/ document- library/EPAR-Product-Information/human/002154/ WC500103049.pdf (2010).
6. Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760-1769 (2011).
7. Taniguchi, H. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 821-829 (2010).
8. Abrahams, B. & Andrews, M. Wells Fargo Equity Research Report (13 April 2011).
9. Friedman, D. & Slifka, S. Joseph Morgan Stanley Report (6 May 2011).